US 12,345,705 B2
Immunochromatographic test strip and immunochromatographic detection kit
Keigo Kohno, Tokyo (JP); Kanako Itou, Tokyo (JP); Shun Sakai, Tokyo (JP); Akira Nakajima, Tokyo (JP); and Motoki Morita, Tokyo (JP)
Assigned to SEKISUI MEDICAL CO., LTD., Tokyo (JP)
Appl. No. 17/294,183
Filed by SEKISUI MEDICAL CO., LTD., Tokyo (JP)
PCT Filed Nov. 19, 2018, PCT No. PCT/JP2018/042627
§ 371(c)(1), (2) Date May 14, 2021,
PCT Pub. No. WO2020/105079, PCT Pub. Date May 28, 2020.
Prior Publication US 2022/0011306 A1, Jan. 13, 2022
Int. Cl. G01N 33/543 (2006.01); G01N 33/531 (2006.01); G01N 33/553 (2006.01); G01N 33/569 (2006.01)
CPC G01N 33/54388 (2021.08) [G01N 33/531 (2013.01); G01N 33/54306 (2013.01); G01N 33/553 (2013.01); G01N 33/56966 (2013.01)] 15 Claims
 
1. An immunochromatographic test strip configured to receive a whole blood specimen comprising at least a sample application region, a development region, and a detection region, wherein the sample application region is pretreated with polyethylene glycol (PEG) having a molecular weight of 15,000 to 700,000,
wherein the sample application region further contains an erythrocyte agglutinating agent or an erythrocyte binding component adapted to prevent the elution and clogging of blood cell components,
wherein the content of the polyethylene glycol per area of the sample application region is 0.00630 to 0.473 mg/cm2,
wherein the immunochromatographic test strip comprises a sample pad as the sample application region, and
wherein the sample pad is made of glass fiber.
 
7. An immunochromatographic test strip comprising at least:
(a) a sample pad made of glass fiber containing polyethylene glycol having a molecular weight of 15,000 to 700,000;
(b) a conjugate pad in which a first specific binding substance binding to an analyte and labeled with colloidal gold is held in a dissolvable state; and
(c) a membrane on which a second specific binding substance binding to an analyte is immobilized, wherein the membrane is a porous membrane,
wherein the sample pad further contains an erythrocyte agglutinating agent or an erythrocyte binding component adapted to prevent the elution and clogging of blood cell components,
wherein the content of the polyethylene glycol per area of the sample application region is 0.00630 to 0.473 mg/cm2.